327 related articles for article (PubMed ID: 21878536)
21. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
22. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
23. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
26. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
27. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
Sakr RA; Barbashina V; Morrogh M; Chandarlapaty S; Andrade VP; Arroyo CD; Olvera N; King TA
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):371-4. PubMed ID: 20216404
[TBL] [Abstract][Full Text] [Related]
28. PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.
Lotan TL; Heumann A; Rico SD; Hicks J; Lecksell K; Koop C; Sauter G; Schlomm T; Simon R
Oncotarget; 2017 Sep; 8(39):65566-65576. PubMed ID: 29029453
[No Abstract] [Full Text] [Related]
29. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
McMenamin ME; Soung P; Perera S; Kaplan I; Loda M; Sellers WR
Cancer Res; 1999 Sep; 59(17):4291-6. PubMed ID: 10485474
[TBL] [Abstract][Full Text] [Related]
30. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
Ronen S; Abbott DW; Kravtsov O; Abdelkader A; Xu Y; Banerjee A; Iczkowski KA
Hum Pathol; 2017 Jul; 65():85-91. PubMed ID: 28504208
[TBL] [Abstract][Full Text] [Related]
31. Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.
Maiques O; Santacana M; Valls J; Pallares J; Mirantes C; Gatius S; García Dios DA; Amant F; Pedersen HC; Dolcet X; Matias-Guiu X
Hum Pathol; 2014 Mar; 45(3):522-32. PubMed ID: 24457075
[TBL] [Abstract][Full Text] [Related]
32. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of
Guedes LB; Almutairi F; Haffner MC; Rajoria G; Liu Z; Klimek S; Zoino R; Yousefi K; Sharma R; De Marzo AM; Netto GJ; Isaacs WB; Ross AE; Schaeffer EM; Lotan TL
Clin Cancer Res; 2017 Aug; 23(16):4693-4703. PubMed ID: 28446506
[No Abstract] [Full Text] [Related]
33. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts.
Harmon SA; Patel PG; Sanford TH; Caven I; Iseman R; Vidotto T; Picanço C; Squire JA; Masoudi S; Mehralivand S; Choyke PL; Berman DM; Turkbey B; Jamaspishvili T
Mod Pathol; 2021 Feb; 34(2):478-489. PubMed ID: 32884130
[TBL] [Abstract][Full Text] [Related]
34. PTEN Loss in a Prostate Cancer Cohort From Jordan.
Al Bashir S; Alzoubi A; Alfaqih MA; Kheirallah K; Smairat A; Haddad H; Al-Dwairy A; Fawwaz BAB; Alzoubi M; Trpkov K
Appl Immunohistochem Mol Morphol; 2020; 28(5):389-394. PubMed ID: 30614821
[TBL] [Abstract][Full Text] [Related]
35. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
36. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
[TBL] [Abstract][Full Text] [Related]
37. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
Shah RB; Bentley J; Jeffery Z; DeMarzo AM
Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T; Berman DM; Ross AE; Scher HI; De Marzo AM; Squire JA; Lotan TL
Nat Rev Urol; 2018 Apr; 15(4):222-234. PubMed ID: 29460925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
